Stock Track | PTC Therapeutics Plummets 5.14% Intraday After Earnings Miss and RBC Price Target Cut

Stock Track
02/20

PTC Therapeutics Inc. (PTCT) shares plummeted 5.14% during intraday trading on Friday, following the release of disappointing quarterly results and a downward revision of its price target by a major analyst firm.

The biopharmaceutical company reported a significant earnings miss for the quarter ended December 31, posting an adjusted loss of $1.67 per share. This result fell far short of the mean analyst estimate for a profit of $0.04 per share. Furthermore, revenue of $213.20 million missed expectations of $276.66 million, and the company reported a quarterly loss of $134.97 million.

Adding to the negative sentiment, RBC Capital maintained its Sector Perform (Hold) rating on the stock but cut its price target to $82 from $87. The analyst action, citing the recent earnings performance, contributed to the selling pressure on PTC Therapeutics shares during the trading session.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10